.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Accenture
Argus Health
Covington
Mallinckrodt
Moodys
Merck
Federal Trade Commission
Cerilliant
Cantor Fitzgerald
Daiichi Sankyo

Generated: September 21, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title: Substituted imino diacids, their preparation and pharmaceutical compositions which contain them
Abstract:Compounds of the general formula: ##STR1## wherein: the ring A is saturated and n=0 or 1, or the ring A is a benzene ring and n=1, R.sub.1 represents a lower alkyl group which can carry an amino group, R.sub.2 represents a hydrogen atom or a lower alkyl group, R.sub.3 represents a straight or branched alkyl group, a mono- or di-cycloalkylalkyl or phenylalkyl group having no more than a total of 9 carbon atoms, or a substituted alkyl group, and also the salts thereof. These compounds are useful as therapeutic drugs.
Inventor(s): Vincent; Michel (Bagneux, FR), Remond; Georges (Versailles, FR), Laubie; Michel (Vaucresson, FR)
Assignee: ADIR (Neuilly-sur-Seine, FR)
Filing Date:Sep 20, 1982
Application Number:06/420,005
Claims:1. Compounds having the general formula: ##STR20## wherein the ring A is saturated and n=1,

R.sub.1 represents a lower alkyl group having from 1 to 4 carbon atoms which can carry an amino group,

R.sub.2 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms,

R.sub.3 represents a straight or branched alkyl group, a monoor di-cycloalkylalkyl group having no more than a total of 9 carbon atoms, or a substituted alkyl group of the formula: ##STR21## with R.sub.4 =H, a lower alkyl (C.sub.1 to C.sub.4) or a cycloalkyl (C.sub.3 to C.sub.6) group,

R.sub.5 32 H, a lower alkyl (C.sub.1 to C.sub.4), a cycloalkyl (C.sub.3 to C.sub.6) or an alkoxycarbonyl group,

Y=S or >N-Q where Q=H, or an acetyl or benzyloxycarbonyl group,

and

p=1 or 2, and

a=0 or 1

in their racemic form or as optical isomers, and the salts thereof obtained with a therapeutically compatible inorganic or organic base, or their addition salts obtained with a pharmaceutically compatible inorganic or organic acid.

2. Compound having the formula: ##STR22## wherein the symbols R.sub.1, R.sub.2 and R.sub.3 have the same meaning as in formula (I) of claim 1, in their racemic form or as optical isomers, and also the salts thereof obtained with therapeutically compatible acids or bases.

3. Compounds according to claim 2, corresponding to the formula (I') in which R.sub.3 is a straight or branched (C.sub.3 to C.sub.8)-alkyl group, a (C.sub.4 to C.sub.8)-cycloalkylalkyl group, or a substituted alkyl group of the formula:

with R.sub.4 =H or an alkyl group and R.sub.5 =an alkoxycarbonyl group, the alkyl and alkoxy groups having from 1 to 4 carbon atoms.

4. Compounds according to claim 2, corresponding to the formula (I') in which R.sub.1 is a methyl radical.

5. Compound of claim 1 being (2S)-1-{N-[(1RS)-1-ethoxycarbonyl-3-methylbutyl]-(S)-alanyl}-2-carboxyperh ydroisoquinoline, its (S) isomer and the sodium salt of these.

6. As pharmaceutical composition containing as active ingredient at least one compound according to claim 1, in conjuction with an inert, non-toxic therapeutically compatible carrier or excipient.

7. A method for treating a patient suffering from hypertension, which comprises administering to said patient a therapeutically effective dose of a compound according to claim 1.

8. Composition of claim 6, wherein the compound is according to any one of claims 2, 3, 4, or 5.

9. Method of claim 7, wherein the compound is according to any one of claims 2, 3, 4, or 5.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Dow
Boehringer Ingelheim
Harvard Business School
Cerilliant
McKesson
McKinsey
Daiichi Sankyo
Cantor Fitzgerald
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot